LR testing demonstrated that LV GLS provided incremental prognostic value over atrial fibrillation (LR χ2 6.24, P = 0.013), RV ejection fraction (LR χ2 4.73, P = 0.030), NYHA class II to IV heart failure symptoms (LR χ2 5.52, P = 0.019), DLCO (LR χ2 5.41, P = 0.020), predicted FVC (LR χ2 3.92, P = 0.048) and LA volume index (LR χ2 4.68, P = 0.030), although it was not incremental over the presence of LGE (LR χ2 3.21, P = 0.073), PASP (LR χ2 2.33, P = 0.13) or LV diastolic dysfunction (LR χ2 1.10, P = 0.29). The gene discussed is CPB1; the disease is atrial fibrillation.